Navigation Links
WuXi PharmaTech Appoints Hao Zhou as Chief Financial Officer

SHANGHAI, May 11 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced that it has appointed Hao Zhou as Chief Financial Officer, effective immediately.

(Logo: )

Mr. Zhou joined the company in May 2009 as Vice President of Finance. His initial responsibilities included financial planning and analysis, ERP system enhancement, tax, and treasury, and he has assumed increasing responsibilities for overall financial operations. As Chief Financial Officer, Hao will report to Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.

Prior to joining WuXi PharmaTech, Mr. Zhou worked for eleven years at General Electric. He held positions of increasing responsibility in financial planning and analysis, enterprise resource planning (ERP) systems, accounting and internal control at GE and was based in Tokyo, London, Shanghai, and several locations in the United States. Most recently he was Finance Director, Greater China, for GE Healthcare Medical Diagnostics and Life Sciences. He also served as an auditor for GE Corporate.

"I am very pleased to announce Hao's promotion to Chief Financial Officer," commented Dr. Ge Li. "With his strong financial background and work ethic, Hao has done an excellent job managing our company's financial operations.

"I also want to thank Ed Hu for serving as a very effective acting Chief Financial Officer for the past year, in addition to his other responsibilities. Hao's appointment allows Ed to concentrate on building our operations and growing our business as our Chief Operating Officer."

Edward Hu, Chief Operating Officer, commented, "I have worked closely with Hao over the past year. He has demonstrated the keen intellect, strong financial expertise, and diligence required of a Chief Financial Officer. I look forward to working with him as WuXi continues to build its capabilities."

Dr. Li concluded, "We look forward to Hao's financial leadership as our growing company broadens its platform of R&D services for the world's pharmaceutical, biotechnology, and medical device companies and prepares to combine with Charles River Laboratories."

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. On April 26, 2010, WuXi and Charles River Laboratories announced that the boards of both companies had reached an agreement for the two companies to combine operations, creating the first global contract research organization offering fully integrated early-stage drug development services to clients worldwide. For more information, please visit: .

    For more information, please contact:

     Stephanie Liu (for the media)
     Tel:   +86-21-5046-4362

     Ronald Aldridge (for investors)
     Tel:   +1-201-585-2048

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. WuXi PharmaTech Announces First-Quarter 2010 Results
2. WuXi PharmaTech Schedules First-Quarter 2010 Earnings Release
3. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
4. WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai
5. WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release
6. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
7. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
8. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
9. Ampio Pharmaceuticals, Inc. Appoints New Chairman and Chief Financial Officer
10. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
11. eCardio Appoints Key Member to Corporate Executive Team
Post Your Comments:
(Date:12/1/2015)... Germany , December 1, 2015 /PRNewswire/ ... leading global manufacturer of eye and gaze tracking solutions, ... SMI remote eye trackers as a component of its ... concussions, eye sight, and medical and performance issues in ... part of SMI,s mass-market-ready eye tracking platform, which is ...
(Date:12/1/2015)... 1, 2015 --> ... van Leeuwenhoek Hospital (NKI-AVL), among the world,s largest ... Leksell Gamma Knife® Icon™, the company,s latest generation ... --> --> With the ... treatments, Leksell Gamma Knife Icon offers greatly enhanced ...
(Date:12/1/2015)... Dec. 01, 2015 ... "Drug Delivery Technology Market 2015 - Forecast ... --> ) has announced the addition ... - Forecast to 2020" report to their ... ) has announced the addition of the ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Physicians’ Education Resource®, LLC ... today announced that the first annual School of Gastrointestinal Oncology™ (SOGO™) will be ... and treatment of gastrointestinal cancers are undergoing transformational change, providing oncologists with powerful ...
(Date:12/1/2015)... ... 2015 , ... Growth in medical payments per workers’ compensation claim in Louisiana ... and nonhospital care, according to a recent study by the Workers Compensation Research Institute ... found medical payments per claim with more than seven days of lost time continued ...
(Date:12/1/2015)... Illinois (PRWEB) , ... December 01, 2015 , ... ... and share medical images have been lifted as IMAGE Information Systems launches MED-TAB™ ... Society of North America Annual Meeting from November 29 to December 4, 2015. ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... , Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. ... results enhancements at the Radiological Society of North America (RSNA) 2015 annual meeting ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... solutions for the care management and population health arenas, is pleased to announce ... and cost containment services, has successfully implemented the ACUITY Complete Care™ Management to ...
Breaking Medicine News(10 mins):